Researcher
Erwin Dreesen
- Disciplines:Biomarker evaluation, Biopharmaceutics, Pharmacodynamics, Pharmacokinetics, Pharmacotherapy, Computational biomodelling and machine learning
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2021 → 30 Sep 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Oct 2019 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Sep 2014 → 30 Sep 2019
Projects
1 - 10 of 15
- Handling of social determinants in pharmacokinetics-pharmacodynamics analyses to enhance equity and inclusion in drug dosing in neonates, children, and adolescentsFrom4 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patientsFrom28 Aug 2023 → TodayFunding: FWO Strategic Basic Research Grant
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Pharmacodynamics models to bridge the gap between exposure and response to antimicrobial treatmentsFrom1 Oct 2021 → 30 Sep 2023Funding: BOF - projects
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Master protocol methodological pharmacometrics researchFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gastrointestinal physiology and drug disposition in geriatric patientsFrom5 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
61 - 70 of 97
- Therapeutic drug monitoring of anti-tumor necrosis factor agents : lessons learned and remaining issues(2020)
Authors: Zhigang Wang, Erwin Dreesen
Pages: 53 - 59 - Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study(2019)
Authors: Erwin Dreesen, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 1248 - 1256 - Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates(2019)
Authors: Bram Verstockt, Erwin Dreesen, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Gert Van Assche, Ann Gils, Séverine Vermeire, Marc Ferrante
Pages: 864 - 872 - Efficacy, pharmacokinetics and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease.(2019)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 317 - 324 - Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease(2019)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 847 - 853 - Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseases(2019)
Authors: Erwin Dreesen, Ann Gils, Séverine Vermeire, Thomas Bouillon
- SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE(2019)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Marc Ferrante, Gils Ann, Séverine Vermeire
Pages: S199 - S199 - PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF RADIOLOGICAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB: A TAILORIX MRE SUBSTUDY(2019)
Authors: Peter Bossuyt, Erwin Dreesen, Jordi Rimola, Sofie De Vuysere, Yves De Bruecker, Ragna Vanslembrouck, Valerie Laurent, Magaly Zappa, Celine Savoye-Collet, Ann Gils, et al.
Pages: S1137 - S1137 - Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases(2019)
Authors: Erwin Dreesen, Ann Gils
Pages: 131 - 141 - Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases.(2019)
Authors: Erwin Dreesen, Ann Gils
Pages: 131 - 141